|
|
Office Locations:
|
223 S. West Street, Suite 900
Raleigh, NC 27603
| | |
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
The RD (Retinal Degeneration) Fund is a 501(c)(3) not-for-profit subsidiary of the Foundation Fighting Blindness. Launched in 2018 as the venture arm of the Foundation and with $72 million under management, the RD Fund focuses on making mission-related investments in companies with projects nearing clinical testing. The RD Fund aims to deliver life-changing solutions for individuals with retinal degenerative diseases today, while also creating a pipeline of next-generation and novel therapeutic opportunities for tomorrow. The RD Fund is flexible in how it structures investments leveraging equity, debt, royalty, and/or project co-funding. All proceeds of this high-impact philanthropic vehicle are returned back to the Foundation to provide resources to further its mission. The fund focuses primarily on companies with programs that are in clinical testing or can be in less than 18 to 24 months, and targets initial investment allocations ranging between $2 and 5 million with appropriate reserves.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
